Acutus Medical Inc. (AFIB): Price and Financial Metrics


Acutus Medical Inc. (AFIB): $2.21

-0.11 (-4.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AFIB POWR Grades


  • AFIB scores best on the Growth dimension, with a Growth rank ahead of 77.42% of US stocks.
  • The strongest trend for AFIB is in Value, which has been heading up over the past 163 days.
  • AFIB's current lowest rank is in the Quality metric (where it is better than 1.85% of US stocks).

AFIB Stock Summary

  • Acutus Medical Inc's stock had its IPO on August 6, 2020, making it an older stock than just 2.08% of US equities in our set.
  • The volatility of Acutus Medical Inc's share price is greater than that of 98.15% US stocks with at least 200 days of trading history.
  • Acutus Medical Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -130.23%, greater than the shareholder yield of only 2.86% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Acutus Medical Inc are CLIR, GTHX, FUV, AAOI, and PTE.
  • AFIB's SEC filings can be seen here. And to visit Acutus Medical Inc's official web site, go to www.acutusmedical.com.

AFIB Valuation Summary

  • AFIB's EV/EBIT ratio is -4.3; this is 114.68% lower than that of the median Healthcare stock.
  • AFIB's price/sales ratio has moved down 130.4 over the prior 13 months.
  • Over the past 13 months, AFIB's price/sales ratio has gone down 130.4.

Below are key valuation metrics over time for AFIB.

Stock Date P/S P/B P/E EV/EBIT
AFIB 2021-08-31 31.5 5.8 -3.7 -4.3
AFIB 2021-08-30 31.9 5.9 -3.8 -4.3
AFIB 2021-08-27 32.9 6.1 -3.9 -4.4
AFIB 2021-08-26 31.9 5.9 -3.8 -4.3
AFIB 2021-08-25 32.5 6.0 -3.8 -4.4
AFIB 2021-08-24 32.4 6.0 -3.8 -4.4

AFIB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AFIB has a Quality Grade of F, ranking ahead of 1.4% of graded US stocks.
  • AFIB's asset turnover comes in at 0.079 -- ranking 159th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows AFIB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.079 -0.743 -0.714
2021-03-31 0.066 -0.876 -0.809
2020-12-31 0.060 -0.877 -0.878

AFIB Price Target

For more insight on analysts targets of AFIB, see our AFIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.67 Average Broker Recommendation 1.6 (Moderate Buy)

AFIB Stock Price Chart Interactive Chart >

Price chart for AFIB

AFIB Price/Volume Stats

Current price $2.21 52-week high $29.95
Prev. close $2.32 52-week low $2.14
Day low $2.14 Volume 44,869
Day high $2.29 Avg. volume 353,085
50-day MA $3.34 Dividend yield N/A
200-day MA $10.44 Market Cap 61.78M

Acutus Medical Inc. (AFIB) Company Bio


Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.


AFIB Latest News Stream


Event/Time News Detail
Loading, please wait...

AFIB Latest Social Stream


Loading social stream, please wait...

View Full AFIB Social Stream

Latest AFIB News From Around the Web

Below are the latest news stories about Acutus Medical Inc that investors may wish to consider to help them evaluate AFIB as an investment opportunity.

Acutus Medical Falls on Canaccord Downgrade

By Sam Boughedda

Yahoo | January 14, 2022

Acutus Medical’s Pulsed Field Ablation System To Be Featured During 27th Annual AF Symposium

CARLSBAD, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the company’s attendance at the 27th Annual AF Symposium. Cases performed at Na Homolce Hospital in Prague, Czech Republic, by physicians Jacob Koruth, M.D., Mount Sinai Health System, Jan Petru, M.D., Na Homolce Hospital, and Vivek Reddy, M.D., Director, Cardiac Arrhythmia

Yahoo | January 13, 2022

A Duo of Net Current Asset Value Stocks to Consider

Short-term investors could be interested in these businesses

Yahoo | January 12, 2022

Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...

New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Pharma A/S, Natera Inc, Anthem Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Orbimed Advisors Llc.

Yahoo | December 24, 2021

Acutus Medicals (AFIB) Buy Rating Reaffirmed at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Acutus Medical (NASDAQ:AFIB) in a research report sent to investors on Monday, TipRanks reports. BTIG Research currently has a $8.00 price target on the stock. AFIB has been the topic of several other reports. Zacks Investment Research downgraded shares of Acutus Medical from a hold rating [] The post Acutus Medicals (AFIB) Buy Rating Reaffirmed at BTIG Research appeared first on ETF Daily News .

ETF Daily News | November 30, 2021

Read More 'AFIB' Stories Here

AFIB Price Returns

1-mo N/A
3-mo -71.95%
6-mo -85.39%
1-year -91.48%
3-year N/A
5-year N/A
YTD -35.19%
2021 -88.16%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7553 seconds.